< Back to previous page
Researcher
Jo Van Ginderachter
- Keywords (Vrije Universiteit Brussel):Applied biological sciences, biotechnology
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Adaptive immunology, Bacteriology
- Disciplines (Vrije Universiteit Brussel):Applied immunology
Affiliations
- Cellular and Molecular Immunology (Research group)
Responsible
From1 Oct 1995 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Jan 2024 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2019 → 31 Dec 2023 - Department of Bio-engineering Sciences (Department)
Member
From8 Apr 2019 → 30 Sep 2019 - Van Ginderachter Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2012 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2010 → 20 Oct 2022 - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 1999 → 30 Sep 2014
Projects
1 - 10 of 26
- Therapeutic targeting of tumor-associated macrophages with anti-CD163 Nanobody-drug conjugates as novel cancer therapyFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Blocking the immunoregulatory family members D-dopachrome tautomerase (D-DT) and Macrophage Migration Inhibitory Factor (MIF) to improve immunotherapy of cancerFrom1 Nov 2022 → TodayFunding: FWO fellowships
- SRP-Onderzoekszwaartepunt: ITAREG: Molecular Imaging and TArgeting of immunoREGulatory cells in Inflammatory diseases and cancerFrom1 Nov 2022 → TodayFunding: BOF - projects
- IOF Accelerator:Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)From1 Oct 2022 → 31 Mar 2024Funding: IOF - technology validation in real environment
- SBO Project : LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
- Optimized anti-Neuropilin-1 Nanobody formats as cancer therapyFrom1 Nov 2021 → TodayFunding: FWO fellowships
- Immunological memory of the macrophage niche (MacNicheMemo).From1 Jan 2021 → TodayFunding: BOF - iBOF
- Blocking Lipocalin-2 (Lcn-2) using Nanobodies as novel cancer therapyFrom1 Nov 2020 → TodayFunding: FWO fellowships
- Seahorse platform: the Agilent Seahorse Flux Analyser with integrated normalization systemFrom1 May 2020 → TodayFunding: Hercules - Small and Medium size research infrastructure
Publications
101 - 101 of 101
- Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model.
Authors: Melissa A. Barber, Tong Zhang, Bethany A. Gagne, Jo A Van Ginderachter, Patrick De Baetselier, Charles L. Sentman
Pages: 655-662
Patents
1 - 6 of 6
- Tumor-associated dendritic cell preparations and uses thereof (Inventor)
- Non-blocking human ccr8 binders (Inventor)
- Human ccr8 binders (Inventor)
- Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages (Inventor)
- A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer (Inventor)
- Murine cross-reactive human ccr8 binders (Inventor)